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an opportunity for earlier 
Diagnosis and Intervention?
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We describe a case of an infant with HSV meningitis and septic shock who demon-
strated a remarkably high serum ferritin level. Aggressive pediatric intensive care and the 
administration of high-dose glucocorticoids were not able to reverse the multiple organ 
dysfunctions. Subsequent autopsy identified the presence of hemophagocytosis, thus 
the patient fulfilled hemophagocytic lymphohistiocytosis (HLH) criteria post-mortem. 
This case highlights that serum ferritin may be an important early indicator of mortality 
in sepsis due to a cytokine storm similar to macrophage activation syndrome and HLH.
Keywords: sepsis, hemophagocytic lymphohistiocytosis, macrophage activation syndrome, HsV, ferritin, 
cytokine storm
Case RepoRt
Patient A, a 5-day-old infant female, 2.2  kg, born prematurely at 35  weeks gestational age, was 
transported to an outside hospital emergency room via emergency medical services following an 
apneic event at home that resolved after the administration of a few rescue breaths by the mother. 
Upon presentation to the emergency room, the patient demonstrated stable vital signs and was 
subsequently transferred to our pediatric intensive care unit (PICU) for respiratory monitoring and 
diagnostic workup for the cause of the apneic event. Upon arrival to the PICU, the patient was vigor-
ous, crying, and tachypneic, but, otherwise, with relatively normal vitals signs (HR 145, BP 77/44, 
97% on 1 LPM NC O2). Given the patient’s age and history of apnea, a workup to rule out serious 
bacterial infection was initiated. Basic labs were sent, and a lumbar puncture was completed showing 
20 WBC/μL (2,030 RBC/μL) with 33% neutrophils. Broad-spectrum antimicrobials were initiated 
including ceftriaxone (50  mg/kg/dose prior to arrival to PICU), acyclovir (60  mg/kg/day), and 
ampicillin (400 mg/kg/day). Initial labs were significant for thrombocytopenia (platelets 39,000/μL) 
but without any other cytopenias (Hgb 17.1 g/dL, WBC 8,760/μL).
At hour 6 after admission, the patient rapidly decompensated and developed lethargy, respiratory 
failure due to apnea, and was intubated and mechanically ventilated. At hour 10 after admission, 
additional laboratory testing revealed very elevated liver transaminases (ALT 2,214, AST > 7,500), 
severe coagulopathy (PT > 120, INR > 16.6, PTT > 200) and a ferritin of 241,000 ng/mL (result 
verified with duplication). The patient’s triglyceride level was 41 mg/dL, and serum lactate level at 
this time was significantly elevated at 14 mmol/L.
At hour 18 after admission, the HSV PCR from CSF returned positive for HSV-2, and the C-reactive 
protein (CRP) was elevated (2.09 mg/dL). We made the preliminary diagnosis of HSV-associated 
hemophagocytic lymphohistiocytosis (HLH) based on a similar case report (1). The patient’s res-
piratory and hemodynamic profile continued to deteriorate (Figure 1A) in spite of escalating vaso-
pressor support (Figure 1B), and the patient needed repeated fluid boluses of colloid (5% human 
serum albumin in NS) and blood product administration (Figure 1C) to maintain mean arterial 
pressure (MAP) of at least 40 mmHg. At this time, 30 mg/kg methylprednisolone was administered 
FIGURe 1 | Vasopressor and fluid resuscitation support needed to maintain a minimum mean arterial pressure (Map) of 40 mmHg. The kinetics of the 
mean arterial blood pressure as determined by non-invasive blood pressure (NIBP) “cuff” (blue line) and continuous invasive blood pressure (CIBP) “arterial line” 
(red line) (a). The dosing of vasopressors, expressed as vasopressor potency, against time (B). Given their higher biologic activity, vasopressor potency for 
epinephrine (red line) and norepinephrine (green line) were calculated as the dose (μg/kg/min) × 100, whereas the vasopressor potency of dobutamine (blue line) was 
calculated as simply the dose of dobutamine (microgram per kilogram per minute). Ongoing fluid resuscitation using both colloid (5% albumin in NS) and blood 
products (including packed red blood cells and fresh frozen plasma) needed to maintain a minimum MAP of 40 mmHg (dotted line) (C).
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to ameliorate the inflammatory process and, with the addition of 
norepinephrine, the patient stabilized transiently, and we were 
able to wean the epinephrine support slightly (Figure 1B).
At hour 30 after admission, the patient again became unstable 
and required repeated volume resuscitation in the form of colloid 
fluid boluses to maintain the MAP goal of 40 mmHg, and then, 
even this MAP goal became unobtainable. After long discussion 
with the parents, it was decided that recovery was unlikely and 
technological support was withdrawn. The parents agreed to an 
autopsy, and the report stated that “the presence of hemophago-
cytosis was demonstrated with the bone marrow and spleen 
exhibiting large cells containing particles consistent with ingested, 
disintegrating blood cells. Given that diagnostic guidelines for 
HLH designate bone marrow, lymph node, and spleen as the 
organs, which most reliably show the histologic features, and sec-
ondary HLH can be triggered by systemic infection, as this patient 
had, the findings post-mortem supported a diagnosis of HLH.”
DIsCUssIoN
We find this case to be of interest given the rapid deterioration of 
a patient with HSV-associated multiple organ dysfunction syn-
drome (MODS). Unfortunately, delivery of anti-inflammatory 
treatment did not significantly affect the outcome. Historically, 
the patient would have been diagnosed with neonatal HSV-
associated fulminant hepatitis (2, 3). However, the patient also 
had a very elevated ferritin level of 241,000 ng/mL. This led us 
to preliminarily diagnose the patient with HSV-associated HLH 
(4). Of the eight criteria proposed in the HLH-2004 guidelines 
(5), our patient met four out of the five requisite criteria for a 
diagnosis of HLH:
 1. Temperature instability (Patient’s Tmin 35.9°C)
 2. Hypofibrinogenemia (Patient’s fibrinogen = 94 mg/dL)
 3. Hyperferritinemia (Patient’s ferritin = 241,000 ng/mL)
 4. Cytopenias (affecting ≥2 out of 3 lineages in the peripheral 
blood)
 5. Platelets <100 × 109/L (Patient’s Plts = 38 × 109/L)
 6. Hemoglobin <9  g/dL in infants <4  weeks of age (Patient’s 
Hgb = 8.1 g/dL).
It is notable that the patient did not have anemia when she was 
first admitted. However, her hemoglobin fell precipitously and 
was maintained at approximately 10 g/dL with packed red blood 
cell (pRBC) transfusions to maintain oxygen carrying capacity in 
light of an ongoing lactic acidosis. The soluble interleukin (IL)-2 
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receptor (sCD25) was sent 28  h after admission and showed a 
value of 755 pg/mL (85.3 U/mL), far less than the 2,400 U/mL 
cut-point defined by HLH-2004 diagnostic criteria. Natural 
killer (NK)-cell activity was not performed though it would be 
expected to be low (6). Furthermore, hemophagocytosis was 
seen on autopsy. Therefore, if one includes the hemophagocytosis 
seen on autopsy, this patient met HLH criteria, and the high dose 
pulse of methylprednisolone seems to have been appropriate. 
Interestingly, following the high dose pulse of methylpredniso-
lone (30 mg/kg), the ferritin fell to 33,600 ng/mL and the CRP to 
0.89 mg/dL at 38-h post-admission.
In terms of risk factors for familial HLH, the parents were nei-
ther related nor were family histories of early unexpected death 
obtained. While not frequently described, case reports reveal that 
hyperferritinemia may be present in disseminated neonatal HSV 
infection. Yamada et al. described a 4-day-old male infant with 
HSV-I infection and a ferritin of >15,000 ng/mL, who seemed 
to respond to methylprednisolone (30 mg/kg/day), intravenous 
immunoglobulin (IVIG, 1 g/kg/day), and whole blood exchange 
transfusion, who recovered completely (1). Imashuku et  al. 
described three neonatal patients (age 3–14  days), who they 
described as fulfilling diagnostic criteria for HLH, who also had 
HSV infection, and who all died as a result of MODS (4). Vladescu 
et al. recently described three neonatal patients (age 6–10 days) 
with HSV infection and hyperferritinemia (>40,000–68,090) (7). 
Of these three patients, the only patient to survive was the patient 
who fulfilled 6 out of 8 criteria for HLH but was not started on 
HLH-2004 therapy due to her improving condition on acyclovir 
alone (7).
These cases invite speculation that hyperferritinemia may be 
a feature of disseminated HSV infection. So, what is the reason 
for the hyperferritinemia during HSV infection and for that mat-
ter, HLH/macrophage activation syndrome (MAS)? Ferritin is a 
key molecule that serves to limit pro-oxidant stress that typifies 
inflammatory conditions (8), and the major source of serum fer-
ritin is tissue macrophages (9). Interestingly, pediatric patients 
with ferritin levels greater than 3,000 ng/mL have an increased 
risk of death (10). While the details are unclear, ferritin expres-
sion by macrophages is induced by pro-inflammatory cytokines 
including IL-1, IL-6, IL-12, IL-18, interferon-gamma (IFN-γ), 
and tumor necrosis factor alpha (TNF-α) (11). Of course, from a 
pediatric intensivist’s perspective, while the cause of the cytokine 
storm is important, stopping it is essential.
Various strategies and therapeutic regimens have been applied 
to HLH and MAS. In 1994, the Histiocyte Society published 
a protocol with the recommendation of an etoposide and 
dexamethasone-based regimen, which remains the basis of initial 
therapy for HLH, with definitive therapy being hematopoietic 
cell transplantation (HCT) (12). For genetic deficiency-verified 
familial HLH, this approach seems very reasonable. However, 
at the present, genetic verification takes weeks, and the admin-
istration of cytotoxic agents to patients with fulminant shock is 
potentially risky. In our case, the hematology/oncology team was 
comfortable with high dose steroids but wanted further lab results 
prior to committing to the etoposide-based regimen. However, 
etoposide may have a role in the acute setting of shock and MAS/
HLH as a preclinical mouse model has shown that it selectively 
depletes activated T lymphocytes (13). To the authors’ knowledge, 
the safety of etoposide administration in a patient with fulminant 
shock has not been studied. Another immuno-modulatory 
approach, therapeutic plasma exchange (TPE) coupled with IVIG 
and methylprednisolone, has been used clinically (14). Given the 
patients’ small size (2.2 kg), placement of an apheresis catheter 
was not attempted and, therefore, TPE was not performed. IVIG 
administration was considered and ordered, but the decision to 
withdrawal of technological support was made before it could be 
administered.
The hyperferritinemia of MAS/HLH most likely represents 
a hypercytokinemic storm, and the targeting of the component 
cytokines, including IL-1, IL-6, and IFNγ, is becoming a target of 
active research (15). In fact, anakina (Kineret), an IL-1 receptor 
antagonist, has been used successfully in similar cases of second-
ary HLH/MAS/MODS (16). In our case, anakinra was not on 
formulary and was unavailable. Ultimately, increased specificity 
and expedited delivery of the diagnosis will be vital to answer the 
question as to the most appropriate therapy. Indeed, much of the 
historical discussion in the literature up to this point regarding 
HLH, MAS, and hyperferritinemic sepsis-related MODS has 
revolved around making the distinction of familial versus sec-
ondary HLH, and the difference in treatment between the two. 
However, may be it is time to change the paradigm of the discus-
sion and, instead, generate a more inclusive criterion that would 
speed diagnosis and treatment of the cytokine storm first, with 
later determination of the cause of the storm. Such a broadened 
criterion may be hyperferritinemic sepsis (HFS), with or without 
MODS. The broadened HFS criterion may expedite diagnosis as 
it would decrease the initial number of hard to obtain laboratory 
values, and, instead, the preliminary criteria would be based on 
clinical findings and an elevated ferritin value alone. It would 
also help clinical research, as the criteria for HLH are strict. The 
simplified criteria for HFS may increase the number of patients 
who would meet eligibility criteria for initial anti-inflammatory 
therapy. While increasing sensitivity, the use of HFS criterion 
would decrease diagnostic specificity of HLH. However, a tiered 
approach to treatment could be undertaken, allowing for earlier 
therapy initiation while diagnostic testing is pending. Absence 
or presence of MODS would impact the risk benefit ratio and 
treatment decisions regarding more aggressive therapies includ-
ing cytokine blockade (16) or TPE (17), and subsequent results 
of genetic testing would dictate the later decisions about HSCT. 
We are not sure, regardless of treatment, if this patient could 
have survived, but we hope that these patients can be captured 
for future research on hyperferritinemic sepsis.
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